针对自身免疫性肝炎的组合疗法的有效性:系统性审查和元分析
Essam Rashad1, Mustafa M Moazam2, Raheel Chaudhry3
1Hospital Medicine, Parkview Regional Medical Center, Fort Wayne, USA.
Cureus
|June 10, 2024
概括
皮质类固醇如普雷迪尼索隆和阿扎西奥普林有效治疗自身免疫性肝炎 (AIH). 这种组合疗法减少了疾病的复发,并改善了AIH管理中的整体患者结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自身免疫性肝炎 (AIH) 是一种肝脏疾病,免疫系统攻击肝细胞.
- 目前针对AIH的治疗策略需要持续评估以获得最佳的疗效.
研究的目的:
- 评估与普雷迪尼索隆和阿扎西奥普林联合治疗自身免疫性肝炎的疗效.
- 综合和分析现有证据,以告知有关AIH治疗的临床实践.
主要方法:
- 进行了对13项研究的系统审查和元分析.
- 在主要的科学数据库 (PubMed,Google Scholar,ScienceDirect,Medline,Embase) 进行了文献搜索.
- 用RevMan 5.4软件进行元分析,并生成森林地块以可视化结果.
主要成果:
- 与普雷迪尼索隆和阿扎西奥普林的联合治疗表明AIH复发率降低.
- 综合治疗方法在自身免疫性肝炎患者中改善了疾病控制.
- 十三项研究的元分析证实了这种治疗策略的有效性.
结论:
- 普雷迪尼索隆和阿扎西奥普林的组合是一种有效的治疗自身免疫性肝炎.
- 这种治疗方案在减少疾病复发和加强控制方面具有好处.
- 证据支持使用这种组合疗法来治疗AIH患者.
相关概念视频
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Autoimmune Disorders
417
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
417
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84


